Michael R. Migden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael R. Migden has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Sirunya Silapunt
Department of Dermatology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas
11 shared publicationsLeon Chen
US Dermatology Partners, 1213 Hermann Dr #650, Houston, TX 77004, USA; Elite Dermatology, 20326, TX-249 Ste 400, Houston, TX 77070, USA
10 shared publications- Sirunya Silapunt
Dermatology, University of Texas Mcgovern Medical School at Houston, Houston, USA
5 shared publications Jigar Patel
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas
4 shared publications- Aleksandar Sekulic
Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.
2 shared publications Alexander Guminski
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia
2 shared publications
Latest Publications
- 25 August 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Impact of Time to Definitive Surgery on Rates of Margin Positivity in Patients With Melanoma: A Study of the National Cancer Database
Was not provided for this article.
- 25 August 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Impact of Time to Definitive Surgery on Rates of Margin Positivity in Patients With Melanoma: A Study of the National Cancer Database
Was not provided for this article.
- Open Access
- 15 April 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 93 (2) , 468-471
Efficacy following discontinuation of sonidegib 200 mg daily treatment in patients with locally advanced basal cell carcinoma: Post hoc analysis of the 42-month BOLT study
- 15 April 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 93 (2) , 468-471
Open AccessEfficacy following discontinuation of sonidegib 200 mg daily treatment in patients with locally advanced basal cell carcinoma: Post hoc analysis of the 42-month BOLT study
- 26 June 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 910-921
Current and emerging intralesional immunotherapies in cutaneous oncology
- 26 June 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (5) , 910-921
Current and emerging intralesional immunotherapies in cutaneous oncology
- Open Access
Non-Melanoma Skin Cancer Detection in the Age of Advanced Technology: A Review
Skin cancer is the most common cancer diagnosis in the United States, with approximately one in five Americans expected to be diagnosed within their lifetime. Non-melanoma skin cancer is the most prevalent type of skin cancer, and as cases rise globally, physicians need reliable tools for early detection. Artificial intelligence has gained substantial interest as a decision support tool in medicine, particularly in image analysis, where deep learning has proven to be an effective tool. Because specialties such as dermatology rely primarily on visual diagnoses, deep learning could have many diagnostic applications, including the diagnosis of skin cancer. Furthermore, with the advancement of mobile smartphones and their increasingly powerful cameras, deep learning technology could also be utilized in remote skin cancer screening applications. Ultimately, the available data for the detection and diagnosis of skin cancer using deep learning technology are promising, revealing sensitivity and specificity that are not inferior to those of trained dermatologists. Work is still needed to increase the clinical use of AI-based tools, but based on the current data and the attitudes of patients and physicians, deep learning technology could be used effectively as a clinical decision-making tool in collaboration with physicians to improve diagnostic efficiency and accuracy.
Open AccessNon-Melanoma Skin Cancer Detection in the Age of Advanced Technology: A Review
Skin cancer is the most common cancer diagnosis in the United States, with approximately one in five Americans expected to be diagnosed within their lifetime. Non-melanoma skin cancer is the most prevalent type of skin cancer, and as cases rise globally, physicians need reliable tools for early detection. Artificial intelligence has gained substantial interest as a decision support tool in medicine, particularly in image analysis, where deep learning has proven to be an effective tool. Because specialties such as dermatology rely primarily on visual diagnoses, deep learning could have many diagnostic applications, including the diagnosis of skin cancer. Furthermore, with the advancement of mobile smartphones and their increasingly powerful cameras, deep learning technology could also be utilized in remote skin cancer screening applications. Ultimately, the available data for the detection and diagnosis of skin cancer using deep learning technology are promising, revealing sensitivity and specificity that are not inferior to those of trained dermatologists. Work is still needed to increase the clinical use of AI-based tools, but based on the current data and the attitudes of patients and physicians, deep learning technology could be used effectively as a clinical decision-making tool in collaboration with physicians to improve diagnostic efficiency and accuracy.
- Open Access
Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma
It is widely known that tumor cells of basal and squamous cell carcinoma interact with the cellular and acellular components of the tumor microenvironment to promote tumor growth and progression. While this environment differs for basal and squamous cell carcinoma, the cellular players within both create an immunosuppressed environment by downregulating effector CD4+ and CD8+ T cells and promoting the release of pro-oncogenic Th2 cytokines. Understanding the crosstalk that occurs within the tumor microenvironment has led to the development of immunotherapeutic agents, including vismodegib and cemiplimab to treat BCC and SCC, respectively. However, further investigation of the TME will provide the opportunity to discover novel treatment options.
Open AccessReview of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma
It is widely known that tumor cells of basal and squamous cell carcinoma interact with the cellular and acellular components of the tumor microenvironment to promote tumor growth and progression. While this environment differs for basal and squamous cell carcinoma, the cellular players within both create an immunosuppressed environment by downregulating effector CD4+ and CD8+ T cells and promoting the release of pro-oncogenic Th2 cytokines. Understanding the crosstalk that occurs within the tumor microenvironment has led to the development of immunotherapeutic agents, including vismodegib and cemiplimab to treat BCC and SCC, respectively. However, further investigation of the TME will provide the opportunity to discover novel treatment options.
- 13 February 2023
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 49 (4) , 343-347
The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose
BACKGROUND: Repair options for Mohs surgical defects include primary closure, flap or graft, or healing by second intention. These options may not be optimal in all cases. A dehydrated complete human placental membrane (dCHPM) allograft may serve as an alternative repair option. OBJECTIVE: To assess the aesthetic and functional outcomes of an alternative repair technique for Mohs surgical defects of the nose. METHODS: Twenty patients with Mohs surgical defects of the nose repaired with a dCHPM allograft were retrospectively identified. Photographs were used to demonstrate surgical technique and outcomes. Two blinded observers evaluated final outcomes using the Patient and Observer Scar Assessment Scale. RESULTS: Observers rated the scar outcome a combined mean score of 8.4 ± 3.2 (scale 5–50). Patients rated their outcomes a mean of 12.6 ± 7.4 (scale 6–60). The mean “Overall Opinion score” was 2.5 ± 1.8 by patients and 1.9 ± 1.3 by observers (scale 1–10). Limitations: This was a single institution study with a small sample size. CONCLUSION: Our study demonstrates that dCHPM allografts are a viable alternative repair option for Mohs surgical defects of the nose.
- 13 February 2023
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 49 (4) , 343-347
The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose
BACKGROUND: Repair options for Mohs surgical defects include primary closure, flap or graft, or healing by second intention. These options may not be optimal in all cases. A dehydrated complete human placental membrane (dCHPM) allograft may serve as an alternative repair option. OBJECTIVE: To assess the aesthetic and functional outcomes of an alternative repair technique for Mohs surgical defects of the nose. METHODS: Twenty patients with Mohs surgical defects of the nose repaired with a dCHPM allograft were retrospectively identified. Photographs were used to demonstrate surgical technique and outcomes. Two blinded observers evaluated final outcomes using the Patient and Observer Scar Assessment Scale. RESULTS: Observers rated the scar outcome a combined mean score of 8.4 ± 3.2 (scale 5–50). Patients rated their outcomes a mean of 12.6 ± 7.4 (scale 6–60). The mean “Overall Opinion score” was 2.5 ± 1.8 by patients and 1.9 ± 1.3 by observers (scale 1–10). Limitations: This was a single institution study with a small sample size. CONCLUSION: Our study demonstrates that dCHPM allografts are a viable alternative repair option for Mohs surgical defects of the nose.
- 28 October 2022
- Published by Elsevier in Dermatologic Clinics
- Vol. 41 (1) , 23-37
Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer
- 28 October 2022
- Published by Elsevier in Dermatologic Clinics
- Vol. 41 (1) , 23-37
Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer
- Open Access
- 18 October 2022
- Published by Elsevier in JAAD International
- Vol. 10, 31-33
Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
- 18 October 2022
- Published by Elsevier in JAAD International
- Vol. 10, 31-33
Open AccessSonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
- Open Access
Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, and patient attributes determine the risk level and acceptable treatment options. Surgical options offer histologic confirmation of tumor clearance. Standard excision provides post-treatment histologic assessment, while Mohs micrographic surgery (MMS) provides complete margin assessment intraoperatively. Additional treatment options may be employed in the correct clinical context. Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.
Open AccessAdvances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, and patient attributes determine the risk level and acceptable treatment options. Surgical options offer histologic confirmation of tumor clearance. Standard excision provides post-treatment histologic assessment, while Mohs micrographic surgery (MMS) provides complete margin assessment intraoperatively. Additional treatment options may be employed in the correct clinical context. Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.
- Open Access
Advances in Cutaneous Squamous Cell Carcinoma Management
CSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.
Open AccessAdvances in Cutaneous Squamous Cell Carcinoma Management
CSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.